Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
June 18, 2024 08:00 ET
|
Novo Nordisk A/S
FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT cardiovascular outcomes trial data evaluating efficacy and safety...
Novo Nordisk A/S - share repurchase programme
June 17, 2024 08:26 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
June 10, 2024 08:15 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
June 03, 2024 10:05 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
May 27, 2024 08:49 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
May 17, 2024 10:20 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 15, 2024 07:23 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
May 13, 2024 11:49 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 08, 2024 11:31 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Trading in Novo Nordisk shares by board members, executives and associated persons
May 06, 2024 15:02 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...